In late September 2004, the cardiovascular risks identified in a placebo-controlled adenoma-prevention trial that was terminated early precipitated the voluntary withdrawal from the market of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib.
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Later that year, in another adenoma -prevention trial, the COX-2 inhibitor, celecoxib, was also associated with an increase in the risk of cardiovascular events. 2 For this reason, on December 17, 2004 , the data and safety monitoring boards of two celecoxib trials recommended stopping drug administration in the trials. 2, 3 Articles describing the cardiovascular risks seen in the two adenoma prevention trials were published rapidly. 1, 4 However, in the absence of evidence about the primary outcome, the occurrence of metachronous adenomas, it was not possible to assess the overall risks and benefits of COX-2 inhibitors in patients with colonic adenomas. 5 In this issue of the Journal, the publication of the primary results of the Adenoma Prevention with Celecoxib (APC) and the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials provides new evidence about the efficacy and the safety profile associated with the use of celecoxib in patients with adenomas. 2, 3 Nonsteroidal antiinflammatory drugs (NSAIDs) vary in the degree to which they inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. The COX-2 selectivity of celecoxib, for instance, is similar to that of diclofenac and sulindac and less pronounced than that of rofecoxib or valdecoxib. 6 Early on, the biology of prostaglandins and their COX-dependent synthesis suggested that the selective COX-2 inhibitors might avert the gastrointestinal bleeding complications associated with traditional NSAIDs. 7 In colon cancers and adenomas, the high levels of expression of COX-2 and the potential cancer-promoting role of its product, prostaglandin E 2 , in epithelial tissue identified COX-2 inhibitors as potentially valuable chemopreventive agents. 8 Inhibition of the production of prostacyclin, which is derived from COX-2, was also hypothesized to have several cardiovascular effects, including the promotion of platelet aggregation, vasoconstriction, and atherosclerosis. 7 Information about the biologic mechanisms of COX-2 inhibition suggests several types of benefits or risks, but obtaining estimates of their magnitude requires studies in human populations.
The placebo-controlled APC and PreSAP trials were well designed and well conducted and had many design features in common, including the age of the patients, the exclusion criteria, the sample size, and the duration of the run-in phase to assess adherence. Patients qualified for entry into these trials only if they had had an adenoma removed during a recent colonoscopy. Both trials planned a three-year duration of the active treatments, and colonoscopies were repeated at one and three years in the two trials. In both trials, the occurrence of any metachronous adenoma was the primary outcome and the occurrence of advanced adenomas was a secondary Although the number of colorectal cancers was small in both trials, the incidence was slightly higher among those receiving celecoxib than among those receiving placebo (a meta -analysis across the two trials showed a relative risk of 1.5; 95 percent confidence interval, 0.5 to 4.7).
These trials together provide convincing evidence that, as compared with placebo, celecoxib prevents metachronous adenomas in patients with a history of adenomas. These findings are consistent with the results of placebo-controlled trials of aspirin for the prevention of adenomas, 9 as well as with a large body of observational evidence suggesting that the use of one of a variety of NSAIDs may reduce the incidence of colorectal cancer by about 50 percent. Combined data from the APC and PreSAP trials, which have been included in a recent metaanalysis, 13 suggest an increase by a factor of about two in cardiovascular risk associated with celecoxib as compared with placebo (Table 1) .
Among patients who have had an adenoma removed, repeated colonoscopy is now generally recommended at intervals of three to five years, depending on pathology-defined risk. 16 Although colonoscopy itself carries risks, an adenoma that is removed does not develop into cancer. The purpose of evaluating a chemopreventive agent such as celecoxib in clinical trials is not to preclude a repeated colonoscopy but to provide evidence about the potential risks and benefits of lengthening the interval between colonoscopies. cardiovascular disease in the control groups from the two trials are similar to estimates from epidemiologic data. Applying clinical -trial risk reductions for advanced adenomas to the incidence of colorectal cancer suggests that celecoxib for the treatment of 1000 patients for three years has a slight advantage over low-dose aspirin (1.6 fewer colorectal-cancer events for celecoxib vs. 1.2 fewer for aspirin). Cardiovascular events were, however, almost five times as common as colorectal cancer (Table 1) . Because aspirin decreases the risk of coronary disease (4.4 fewer events in 1000 patients followed for three years), and because celecoxib increases the risk of coronary disease (12.7 extra events), the use of celecoxib in 1000 patients for three years, under the assumptions of this simple risk-benefit analysis, results in 16.7 more colorectal-cancer and cardiovascular events than treatment with low-dose aspirin and in 11.1 more events than no treatment at all.
According to evidence from the Preventive Services Task Force, low-dose aspirin is likely to be associated with 3 (95 percent confidence interval, 2 to 4) major gastrointestinal bleeding events among 1000 patients who are followed for five years.
14 Other reasonable estimates of the incidence and the risks of serious gastrointestinal bleeding, colorectal cancer, and cardiovascular events, as well as other reasonable weights assigned to the two dominant clinical events in this hypothetical analysis, are unlikely to alter substantially the projected three-year risk-benefit profile associated with celecoxib. Although the prevention of colorectal cancer in patients with adenomas may require treatment or follow-up for more than three years, established practice guidelines for patients with adenomas limit the available duration of treatment to the interval between repeated colonoscopies. 16 In summary, these two trials provide strong evidence that among patients with colonic adenomas, the use of celecoxib for up to three years reduces the risk of metachronous adenoma.
These placebo-controlled trials were too small to evaluate the role of celecoxib in preventing colorectal cancer. Nevertheless, in these same studies, significant cardiovascular risks were demonstrated. In patients with adenomas who undergo repeated colonoscopies, the increase in cardiovascular events caused by celecoxib outweighs what may be an optimistic projection of its potential benefit in decreasing colorectal-cancer events. It is reasonable to conclude that celecoxib has no role as a chemopreventive agent either in patients with nonfamilial colonic adenomas or in the general population. 
